TY - JOUR T1 - Exposure to attention deficit hyperactivity disorder medications during pregnancy JF - Canadian Family Physician JO - Can Fam Physician SP - 1153 LP - 1155 VL - 53 IS - 7 AU - Caitlin Humphreys AU - Facundo Garcia-Bournissen AU - Shinya Ito AU - Gideon Koren Y1 - 2007/07/01 UR - http://www.cfp.ca/content/53/7/1153.abstract N2 - QUESTION An 18-year-old patient of mine, currently under treatment for attention deficit hyperactivity disorder (ADHD) with methylphenidate, just found out that she is pregnant. What are the risks for the baby when the mother uses ADHD medications during pregnancy? ANSWER Available evidence for amphetamines suggests no increased risk of malformations with use of therapeutic doses, and inadvertent exposure during pregnancy is unlikely to be harmful. Human data for methylphenidate and atomoxetine treatment in pregnancy are very limited. Documented cases do not suggest teratogenicity, but we cannot rule out this risk with the information available. ER -